1Smith G,Hosker H. Diagnosing and treating atypical pneumonia.The Practitioner, 2001,245(1626):736.
2Poenkae A,Poenkae T,Sarna S,et al. uestionable Specificity of Lipid Antigen in the Mycoplasma pneumoniae Complement Fixation Test in Patients With Extrapulmonary Manifestations. Journal of Infection , 1981,3( 4):332.
3Chergui K,Fourme T,Veillard-Baron A,et al.Mycoplasma pneumoniae and second-degr-ee heart block. Clinical infectious diseases : an official publication of the infectious diseases. Society of America, 1998 ,27(6):1534.
4Chen S C,Tsai C C,Nouri S C. Carditis associated with Mycoplasma pneumoniae infection. Am J Dis Child,1986,140(5):471.
5Paze,Potasman I.Mycoplasma-associated carditis.Case report and review.Cardiology,2002,97(2):83.
6Prattichizzo F A, Simonetti I, Caletta F. Carditis associated with mycoplasma pneumoniae infection clinical aspects and therapeutic problems.Minerva Cardiangiologica,1997,45(9):447?A?A.
同被引文献14
1李梦东.实用传染病学[M]北京:人民卫生出版社,1998322.
2SINATRA S T. Metabolic cardiology:an integrative strategy in the treatment of congestive heart failure[J].Alternative Therapies In Health and Medicine,2009,(03):44-52.
3DI NAPOLI P. The metabolic treatment of coronary artery disease and heart failure[J].Current Pharmaceutical Design,2009,(08):826.doi:10.2174/138161209787582129.
4FRAGASSO G,SALERNO A,SPOLADORE R. Metabolic therapy of heart failure[J].Current Pharmaceutical Design,2008,(25):2582-2591.doi:10.2174/138161208786071245.
